Importantly, inhibition of baseline Notch signaling in fully transformed human cell lines did not alter sensitivity to GPX4 inhibition, further supporting the conclusion that Notch activation at tumor inception forces an astrocytic developmental trajectory with altered mitochondrial activity but Notch activation later in tumor development is not sufficient to induce similar cell states, metabolic programs, or therapeutic vulnerabilities. The gene discussed is GPX4; the disease is neoplasm.